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Technology for monitoring in vivo microRNA (miRNA) activity is extremely important for elucidating miRNA biology. 
However, in vivo studies of miRNA have been hampered by the lack of a convenient approach to reliably reflect real-time 
functional changes in miRNAs. Sensors for miRNA were developed by adding miRNA target sequences to the 3′-untranslated 
region of Gaussia princeps luciferase (Gluc) mRNA. These sensors were then evaluated in vitro and in vivo by measuring Gluc 
activity in cell supernatants and in peripheral blood. Sensors driven by the CMV promoter were effective for monitoring 
miR-122 in living cells, but not for the long-term monitoring of miR-122 or miR-142 in mouse liver because of 
CMV-promoter silencing. Replacing the CMV promoter with a CAG promoter rendered these sensors effective for the 
long-term monitoring of relevant liver miRNA activities. We subsequently used the CAG-promoter-based sensor for the 
long-term monitoring of endogenous liver miR-122, miR142 and miR-34a activities, as well as for exogenous miR-34a activity. 
Our study demonstrates that real-time in vivo activities of miRNAs can be continuously and conveniently detected in mouse 
liver using the sensors that we have developed.  
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MicroRNAs (miRNAs) are a class of endogenous, small, 
functional RNAs of 19–23 nt. Mature miRNAs bind to 
complementary sequences in the 3′-untranslated regions 
(UTRs) of target mRNAs and cause either translational re-
pression or mRNA degradation, and hence regulate protein 
expression [1–4].  
Current approaches for miRNA detection are mainly 
based on Northern blotting, reverse transcription quantita-
tive PCR (RT-qPCR) and microarray analysis [5–7]. While 
these methods have been widely used, they are both 
time-consuming and laborious. Furthermore, they do not 
reflect the real-time function of a given miRNA in living 
cells. A few miRNA “sensors”, constructed by inserting a 
given miRNA target sequence into the 3′-UTR of reporter 
genes, including lacZ [8], GFP [9] and luciferase [10–12], 
have been reported. Using these sensors, miRNA activity 
can be inferred by measuring the inhibition of reporter gene 
expression. Although these sensors may reveal the spatio-
temporal expression patterns of miRNAs in tissues and may 
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advance our understanding of miRNA functions, their use-
fulness in living organisms has not been fully evaluated. 
Furthermore, these sensors were not developed for the pur-
pose of continuous and convenient ex vivo monitoring of in 
vivo miRNAs. Thus, miRNA sensors can be improved. 
Recently, a secreted luciferase, Gluc, from the marine 
copepod Gaussia princeps has been used as a sensitive and 
quantitative tool for the in vivo non-invasive monitoring of 
transduced tumor cells inoculated in mice [13–15]. Tumor 
expansion can be monitored easily by measuring Gluc ex-
pression in blood. Thus, Gluc is an ideal candidate for im-
proving miRNA sensors. In the present study, we generated 
a series of miRNA sensors by inserting miRNA target se-
quences into the 3′-UTR of the Gluc gene, and evaluated the 
suitability of different promoters for use in the mouse liver. 
We demonstrate that a CAG/Gluc-miRT sensor can be used 
to continuously and conveniently monitor miRNAs in 
mouse liver. 
1  Materials and methods 
1.1  Sensor construction 
All sensors generated contained three major elements: a 
CMV or CAG promoter (the latter being a composite pro-
moter consisting of the CMV IE enhancer, the chicken 
β-actin promoter, and a rabbit β-globin polyadenylation 
signal); a Gluc reporter gene derived from pGluc-Basic 
(New England Biolabs, Ipswich, USA); and four repeats of 
miR-122, miR-142 or miR-34a target sequences in the 
3′-UTR of the Gluc gene. These elements were cloned into 
an adeno-associated virus serotype 2 (AAV2) expression 
vector with inverted terminal repeat (ITR) sequences flank-
ing the transgene. We named the resulting sensors CMV/ 
Gluc-miR-122T and CAG/Gluc-miR-122T; CMV/Gluc-miR- 
142T and CAG/Gluc-miR-142T; and CMV/Gluc-miR-34aT 
and CAG/Gluc-miR-34aT (Figure 1A). The following oli-




ACACTCCAA-3′ and 5′-GATCTTGGAGTGTGACAATG- 
GTGTTTGGTCTTGGAGTGTGACAATGGTGTTTGGT- 
CTTGGAGTGTGACAATGGTGTTTGGTCTTGGAGTG- 




3′ and 5′-GATCTTGTAGTGTTTCCTACTTTATGGAGT- 
CTTGTAGTGTTTCCTACTTTATGGAGTCTTGTAGTG- 
TTTCCTACTTTATGGAGTCTTGTAGTGTTTCCTACTT- 
TATGGAG-3′; and miR-34a, 5′-AATTCACAACCAGCT- 
AAGACACTGCCAAGACACAACCAGCTAAGACACT- 
GCCAAGACACAACCAGCTAAGACACTGCCAAGAC- 
ACAACCAGCTAAGACACTGCCAA-3′ and 5′-GATCT- 
TGGCAGTGTCTTAGCTGGTTGTGTCTTGGCAGTGTC- 
TTAGCTGGTTGTGTCTTGGCAGTGTCTTAGCTGGTT- 
GTGTCTTGGCAGTGTCTTAGCTGGTTGTG-3′. Gluc ex- 
pression plasmids under the control of the CMV or CAG 
promoter without miRNA binding sites were also constructed 
as controls and were named CMV/Gluc or CAG/Gluc. A 
firefly luciferase (Fluc) expression plasmid under the con-
trol of the CMV promoter without miRNA binding sites 
was also constructed as an internal control for the 
Gluc-based sensor and was named CMV/Fluc. The 
pre-miR-122 and pre-miR-34a genes were amplified from 
genomic DNA of HEK 293 cells by PCR using the follow-
ing primers: pre-miR-122, 5′-ACTGCAGAATTGATCA- 
CATTTAC-3′ (forward) and 5′-CAGTAAGTACACAAG- 
ATTGAGAAG-3′ (reverse); pre-miR-34a, 5′-GCCTCCTG- 
CATCCTTTCTTTC-3′ (forward) and 5′-CCTGTGCCTTT- 
TTCCTTCCG-3′ (reverse).  
1.2  In vitro sensor evaluation 
Huh7, HeLa and HEK 293 cells were cultured in Dul-
becco’s modified Eagle’s medium supplemented with 10% 
fetal bovine serum at 37°C in 5% CO2. Cells were trans-
fected with sensors using Lipofectamine 2000 (Invitrogen, 
Carlsbad, USA) in accord with the manufacturer’s instruc-
tions. The levels of Gluc in the cell-culture supernatants 
were subsequently measured, to allow the functionality and 
sensitivity of the sensors to be evaluated. 
1.3  In vivo sensor evaluation 
Male BALB/c mice, 5–6 weeks old, were housed in patho-
gen-free conditions at the Institute of Laboratory Animal 
Science, Chinese Academy of Medical Sciences (Beijing, 
China). All procedures involving animals were conducted in 
accord with institutional guidelines, which comply with 
national and international regulations and guidelines. Sen-
sors were delivered by hydrodynamic tail vein (HTV) injec-
tion as described previously [16]. Briefly, sensors were di-
luted in a volume of normal saline (in mL) equivalent to 
10% of the average body weight (in g) and were slowly 
injected manually into the lateral tail vein, over the course 
of 6–7 s. To evaluate sensor function, 2.5 μL blood samples 
were collected at different time points by making small in-
cisions in the tail, and Gluc activity was determined using a 
commercial Gaussia luciferase assay kit (New England 
Biolabs) in accord with the manufacturer’s instructions. The 
number of photons produced in a 10 s window was counted 
using a luminometer (Turner BioSystems, Sunnyvale, 
USA). 
1.4  In vivo bioluminescent imaging 
Twenty-four hours after hydrodynamic injection of CMV/  




Figure 1  Gluc-miRT sensors and in vitro assessment of the CMV/Gluc-miR-122T sensor. A, The Gluc-miRT sensor was constructed by inserting four 
repeats of the target sequence of mature miRNA between the Gluc gene and the polyadenylation (polyA) site (upper). A Gluc expression plasmid without 
miRNA target sequences was constructed as a control (bottom). Gluc, Gaussia princeps luciferase; miRT, miRNA target sequences; CMV, human cy-
tomegalovirus promoter; CAG, CMV early enhancer/chicken β-actin promoter; ITR, inverted terminal repeat from adeno-associated virus serotype 2. B, 
CMV/Gluc-miR-122T was transfected alone or with pmiR-122 into Huh7 cells (left) or HeLa cells (right). Gluc activity in cell culture medium was detected  
on days 1–5. The results are presented as means±SD (n=3). pmiR-122, plasmid encoding pre-miR-122; RLU, relative light units. 
Fluc, 150 mg kg−1 body weight of D-luciferin (Molecular 
Imaging Products, Bend, USA) was injected intraperito-
neally into mice. Ten minutes later, mice were anesthetized 
by intraperitoneal injection of 75 mg kg−1 body weight of 
sodium pentobarbital. Images were acquired 5 min after 
sodium pentobarbital injection. The whole-body images for 
luciferase activity were acquired for 10 s using an IVIS im-
aging system (Xenogen, Hopkinton, USA).  
1.5  miRNA quantification 
To eliminate any nonspecific miRNA changes, total RNA 
was isolated from mouse livers using a mirVana™ miRNA 
isolation kit (Ambion, Austin, USA). Reverse-transcription 
quantitative PCR was performed using a mirVana™ 
RT-qPCR miRNA detection kit (Ambion) in conjunction 
with the has-miR-122 and has-miR-142-3p primer sets 
(Ambion) in accord with the manufacturer’s instructions. 
The mouse snoRNA202 primer set (Ambion) was used as a 
control. To determine absolute copy numbers, a standard 
curve was generated using HPLC-purified RNA oligonu-
cleotides corresponding to miR-122 or miR-142-3p (Invi-
trogen, Shanghai, China). 
2  Results 
2.1  In vitro assessment of the CMV/Gluc-miR-122T 
sensor 
The CMV/Gluc-miR-122T miRNA sensor was constructed 
as described in the Materials and methods section (Figure 
1A). The Gluc expression plasmid without miR-122 binding 
sites, CMV/Gluc, was also constructed as a control (Figure 
1A). To determine whether the sensor effectively measures 
the level of miR-122 in cells, we transfected CMV/Gluc- 
miR-122T into Huh7 cells, which express miR-122 at high 
levels and into HeLa cells, which are negative for miR-122 
expression [17]. Levels of Gluc secreted into the super-
natant were assayed on days 1–5 after transfection. The 
growth medium was replaced every day to avoid Gluc ac-
cumulation. The supernatants of Huh7 cells transfected with 
CMV/Gluc-miR-122T showed consistently low levels of 
Gluc, with activities of (1385±126), (30089±8066), (40894± 
10917), (54402±18958) and (30335±3406) relative light 
units (RLU) on days 1–5, respectively. Conversely, super-
natants from control cells showed consistently high levels of 
Gluc activity: (35661±7469), (874808±207580), (1355468± 
185778), (1125206±41611), (1211542±205606) RLU on 
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days 1–5, respectively (Figure 1B). Gluc levels in super-
natants of HeLa cells transfected with CMV/Gluc-miR- 
122T and with control constructs were similar on days 1 and 
5 (Figure 1B). To confirm that the repression of Gluc was 
dependent on miR-122, Huh7 and HeLa cells were 
co-transfected with CMV/Gluc-miR-122T and a plasmid 
expressing miR-122 (pmiR-122). HeLa cells transfected with 
CMV/Gluc-miR-122T and pmiR-122 showed marked Gluc 
repression on days 1−5, with Gluc activity levels of 
(104107±4547), (335557±147215), (73922±22262), (67866± 
19776) and (38551±10334) RLU, compared with the activity 
levels in cells transfected with CMV/Gluc-miR-122T alone 
((990217±333802), (9782300±2973113), (14623065± 
2256744), (16681655±3120897) and (11183016±2024543) 
RLU on days 1–5; Figure 1B). In Huh7 cells, co-transfec-    
tion with pmiR-122 enhanced the repression of Gluc (activ-
ity (986±64), (14933±3337), (9961±1301), (8638±4530) 
and (7192±2067) RLU on days 1−5), whereas pmiR-122 
further repressed Gluc activity only slightly (Figure 1B). 
These data suggest that Gluc was repressed by native and 
transduced miR-122 and that this repression was detected 
consistently by our CMV/Gluc-miR-122T sensor. Further-
more, our CMV/Gluc-miR-122T sensor could be used to 
monitor the real-time kinetics of miR-122 activity by meas-
uring the levels of Gluc in the culture medium. 
2.2  In vivo assessment of CMV/Gluc-miRT sensors 
We then determined whether the CMV/Gluc-miR-122T sen-
sor could be used to monitor miR-122 levels in mouse hepa-
tocytes which express miR-122 at very high levels [17]; 
miR-122 is estimated to account for 70% of the total liver 
miRNA content [18]. In addition to the plasmids CMV/Gluc 
and CMV/Gluc-miR-122T, the non-secreted Fluc express-
ing plasmid, CMV/Fluc, was constructed as an internal con-
trol (described in the Materials and methods section). One 
group of mice was inoculated with 10 μg of CMV/Gluc and 
10 μg of CMV/Fluc by HTV injection. Another group of 
mice was inoculated with the same amount of CMV/ 
Gluc-miR-122T and CMV/Fluc. Twenty-four hours after 
injection, Gluc activity was detected in 2.5 μL blood sam-
ples and Fluc activity was quantified using an IVIS imaging 
system. There was no significant difference between Fluc 
activity in mice co-injected with CMV/Fluc+CMV/Gluc 
((2.50×108±1.08×108) RLU; Figure 2A and C) or CMV/ 
Fluc+CMV/Gluc-miR-122T ((2.32×108±1.48×108) RLU; 
Figure 2B and C). The Gluc activity in mice co-injected 




Figure 2  Detecting the activity of Gluc or Fluc in mice following co-injection of CMV/Gluc-miR-122T sensor and CMV/Fluc. A, Imaging of Fluc in mice 
co-injected with CMV/Fluc+CMV/Gluc. B, Imaging of Fluc in mice co-injected with CMV/Fluc+CMV/Gluc-miR-122T. C, Summary of A and B, Gluc 
blood assays of mice co-injected with CMV/Fluc+CMV/Gluc or mice co-injected with CMV/Fluc+CMV/Gluc-miR-122T. The results are presented as  
means±SD (n=3). 
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showed a 696.9-fold decrease compared with mice co-in-    
jected with CMV/Fluc+CMV/Gluc ((4768176±499358) 
RLU; Figure 2C). These data showed that Gluc of the 
CMV/Gluc-miR-122T sensor was significantly repressed by 
native miR-122 in mouse liver and that the inhibition of 
Gluc reflected the activity of miR-122. These results also 
confirmed that the change in Gluc activity was influenced 
by the insertion of miRNA target sites. 
Sensor dose effect was then assessed. We delivered 0.1, 
1, 10, or 50 μg of CMV/Gluc-miR-122T sensor by HTV 
injection into mouse hepatocytes and Gluc was monitored 
continuously in 2.5-μL blood samples from 2 to 96 h after 
injection. All four doses of miR-122 sensor showed similar 
efficiency for monitoring miR-122 in vivo (Figure 3A–D). 
For example, in mice injected with a 10 μg dose of CMV/ 
Gluc-miR-122T, the Gluc activities were (28543±5447), 
(39883±16693), (29172±2216), (33517±10103), (33047± 
9510), (18970±735), (6625±791), (1703±116), (438±60) 
and (275±36) RLU at 2, 4, 6, 8, 10, 12, 24, 48, 72 and 96 h, 
respectively. The corresponding Gluc activities in controls 
were (301251±27622), (1680742±323635), (4251860± 
668420), (6377790±1002630), (9496617±1003472), (8070357± 
1366697), (4679858±706044), (1584957±170868), (253340± 
54503) and (37228±10340) RLU at 2, 4, 6, 8, 10, 12, 24, 48, 
72 and 96 h, respectively. Thus, the extent of repression was 
as high as 706.4-fold at 24 h (Figure 3C).  
 
 
Figure 3  In vivo assessment of the CMV/Gluc-miR sensors. BALB/c mice received 0.1 μg (A), 1 μg (B), 10 μg (C), and 50 μg (D) of CMV/Gluc- 
miR-122T by HTV injection and blood Gluc activity was measured. E, CMV/Gluc-miR-142T (10 μg) was delivered into BALB/c mice by HTV injection, 
and blood Gluc activity was measured. The results are presented as means±SD (n=4). F, miRNA quantification. Total RNA was isolated from the livers of 
BALB/c mice immediately before and 72 h after injection of CMV/Gluc-miR-122T or CMV/Gluc-miR-142T and miRNA levels were quantified by  
RT-qPCR using primers and probes specific for miR-122 or miR-142. The results are presented as means±SD (n=4). 
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To determine the specificity of the CMV/Gluc-miR-122T 
sensor, we replaced the miR-122 target sequence with that 
of miR-142-3p (miR-142), which is expressed at low levels 
in the liver [19,20]. When CMV/Gluc-miR-142T (10 μg) 
was delivered to the mouse liver by HTV injection, no re-
pression of Gluc activity by miR-142 was observed within 
12 h of injection. Gluc activity subsequently declined 
slightly to (2413456±635134), (211951±49479), (17665± 
2705) and (11892±2235) RLU at 24, 48, 72 and 96 h after 
injection, respectively; the extent of repression was only 
1.9–14.3 fold at 24–96 h (Figure 3E). Taken together, these 
observations indicate that our miRNA sensor reliably and 
conveniently detected the relevant miRNA in mouse liver. 
2.3  RT-qPCR analysis of miR-122 and miR-142 in 
mouse liver 
Gluc levels in mouse liver decreased after 24 h after injec-
tion under all test conditions. There are two possible expla-
nations for this observation. First, HTV injection injury and 
the plasmids may trigger miRNA expression in the liver, 
thus leading to repression of the target, Gluc. Alternatively, 
the decrease may result from silencing of the CMV pro-
moter in the mouse liver [21]. To examine whether HTV 
injection or the miRNA sensor itself affected the levels of 
miRNAs in the liver, we determined the levels of miR-122 
and miR-142 in mouse liver by RT-qPCR, immediately 
before and 72 h after injection. The miR-122 content (cop-
ies/ng RNA) in mouse liver was (1.20±0.46)×108 and 
(1.23±0.49)×108 before and after injection of CMV/Gluc- 
miR-122T, respectively. For miR-142, these values were 
(3.88±1.67)×106 and (3.64±1.33)×106 before and after in-
jection of CMV/Gluc-miR-142T (Figure 3F). Consistent 
with previous data, these observations indicate that miR-122 
is dominant in mouse liver. Moreover, the lack of change in 
miR-122 or miR-142 levels before and after injection indi-
cates that HTV did not alter the expression of liver miRNAs 
and that the expression of miRNA binding sites in the liver 
did not produce obvious depressive effects on the relevant 
miRNAs. 
2.4  Long-term monitoring of endogenous miR-122 and 
miR-142 in the mouse liver using CAG/Gluc-miRT 
To determine the factors responsible for the rapid decrease in 
Gluc levels 24 h after injection and to improve our sensor, we 
replaced the CMV promoter in CMV/Gluc-miR-122/142T, 
as well as in the control, with a CAG promoter to construct 
CAG/Gluc-miR-122/142T and CAG/Gluc, respectively 
(Figure 1A). The CAG promoter has been reported to be an 
excellent alternative to the CMV promoter for hydrody-
namic delivery of genes to the liver [22]. CMV/Gluc, 
CAG/Gluc, CAG/Gluc-miR-122T or CAG/Gluc-miR-142T 
at the dose of 10 μg was delivered to mice by HTV injec-
tion and Gluc blood assays were performed. Although Gluc 
activity for CMV/Gluc declined enormously from 
(8070357±1366697) RLU at 12 h to (687±101) RLU at 25 
days (Figure 4A), Gluc activity for CAG/Gluc remained 
stable for a long time, decreasing to its lowest level 
((459226±53049) RLU) at day 25; this level was only 
4.2-fold lower than the peak Gluc activity ((1943818± 
499679) RLU), recorded at 6 h, and 2.0-fold lower than the 
Gluc activity at 48 h ((951915±75173) RLU; Figure 4A). 
Taken together, these observations indicate that the CMV 
promoter was responsible for the rapid decrease in Gluc 
expression in the early stages of the original experiments 
and that the CAG promoter is an important element for 
long-term monitoring of miRNA in the liver. The Gluc ac-
tivity of CAG/Gluc-miR-122T was depressed 3 h after in-
jection and remained at a relatively stable level ranging 
from (1239±381) RLU (highest level at 72 h) to (918±39) 
RLU (lowest level at day 15) from 24 h to 25 days 
post-injection (Figure 4A). The degree of repression of 
miR-122 was stable at 502.9- to 766.4-fold from 48 h after 
injection to day 25. For miR-142, Gluc activity was 
(140773±37653) RLU (highest level at 48 h) to (50631± 
5796) RLU (lowest level at day 20) from 48 h after injec- 
 
 
Figure 4  Long-term in vivo assessment of CAG/Gluc-miRT sensors. A, 
Monitoring of miR-122 and miR-142 activities in mouse livers. CMV/Gluc, 
CAG/Gluc, CAG/Gluc-miR-122T or CAG/Gluc-miR-142T was delivered 
into BALB/c mice by HTV injection, and blood Gluc activity was meas-
ured. The results are presented as means±SD (n=4). B, Monitoring 
miR-34a in mouse liver. CAG/Gluc-miR-34aT was delivered into BALB/c 
mice alone or together with pmiR-34a by HTV injection, and blood Gluc 
activity was measured. The results are presented as means±SD (n=4).  
pmiR-34a, plasmid encoding pre-miR-34a. 
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tion to day 25 (Figure 4A), representing stable repression 
for miR-142 of 6.8- to 9.3-fold. These results indicate that 
compared with CMV/Gluc-miRTs, CAG/Gluc-miRTs de-
tected miRNA levels more consistently and for a longer 
period. Moreover, these results demonstrate that miRNA 
levels were not affected by miRNA sensor injection. In con-
clusion, long-term expression of miRNA sensors driven by 
the CAG promoter allowed reliable and sensitive monitor-
ing of miRNAs in mouse liver. 
2.5  CAG/Gluc-miRT is also suitable for monitoring 
changes in exogenous miRNA activity in the liver 
Having established a sensitive sensor for long-term moni-
toring of endogenous native miRNAs in vivo, we next 
evaluated the application of CAG/Gluc-miRTs to real-time 
monitoring of exogenous miRNAs in the liver. We per-
formed HTV injection of 10 μg of CAG/Gluc-miR-34aT 
(encoding the miR-34a target sequence, with miR-34a being 
expressed at low levels in the liver [20]) into one group of 
mice to detect endogenous miR-34a in the liver. In a paral-
lel experiment, 10 μg of CAG/Gluc-miR-34aT and 10 μg of 
pmiR-34a (a plasmid encoding miR-34a) were co-trans-     
fected into another group of mice, to study the effect of 
miR-34a overexpression on its target. Similar to the 
miR-142 sensor described above, the Gluc activity from 
CAG/Gluc-miR-34aT was slightly repressed from 3 h after 
injection. This repression was increased at 24 h ((124960± 
15213) RLU), and remained stable (lowest level, (45017± 
8349) RLU at day 20) until day 25 (Figure 4B). The degree 
of repression for CAG/Gluc-miR-34aT was 7.9- to 10.8- 
fold from 24 h. These results reflect the low level of native 
miR-34a in mouse liver. For co-transfection with pmiR-34a, 
slight repression, similar to that observed with CAG/Gluc- 
miR-34aT alone, was detected at 3–6 h post-injection, but 
the Gluc activity decreased markedly from 12 h ((284865± 
123674) RLU), falling to (19113±8412) RLU at 24 h, and 
then to (2503±446) RLU at 48 h, before remaining stable at 
a low level (lowest level, (1129±140) RLU at day 15) until 
day 25 (Figure 4B). The degree of repression for CAG/ 
Gluc-miR-34aT in the pmiR-34a-co-transfection group was 
319.9- to 437.5-fold from 48 h post-injection, and the 
greatest repression was observed 48–72 h after injection. 
These observations suggest that our miRNA sensors may 
also be useful for monitoring changes in exogenous miRNA 
activity in vivo. 
3  Discussion 
Since their discovery in 1993, miRNAs have been reported 
to have roles in development, embryogenesis, differentia-
tion, organogenesis, growth control, programmed cell death, 
human diseases such as cancer and the inhibition of viral 
replication [1,4]. Northern blot analysis continues to be 
widely used as the standard miRNA detection method. 
Other detection techniques and tools, such as quantitative 
RT-PCR and microarrays, provide greater sensitivity or 
higher-throughput and require lower amounts of starting 
material [6,7]. However, these methods are time-consuming 
and cannot provide real-time information regarding changes 
in miRNA levels and functionality. Furthermore, these 
methods cannot be applied repeatedly to the same subject. 
miRNA sensors, containing miRNA binding sites in re-
porter gene mRNAs, have been used to detect the presence 
and function of miRNAs in cells [8]. These sensors have 
been applied to the analysis of miRNA regulation in the 
liver [23,24], notably for miR-122, which is specifically and 
abundantly expressed in the liver. For noninvasive measur-
ing of miRNAs, optical imaging techniques using 
luciferase-based miRNA sensors have been used in several 
studies, such as in vivo imaging of miR-221 biogenesis in 
papillary thyroid carcinoma [10] and evaluation of miR-122 
regulation in mouse liver in a single mouse at different time 
points [25]. Although these techniques provide a non-in-    
vasive means of continuously monitoring in vivo miRNA 
activity in a single animal, faster and more convenient 
methods are still needed. 
In the present study, we established a series of novel 
Gluc-miRT miRNA sensors that allow convenient monitor-
ing of miRNAs in a single animal at different time points. In 
in vitro studies, these sensors can be used to measure 
miRNA activity by detecting Gluc in cell supernatants, 
without the need for cell lysis; the amounts of active 
miRNA produced within different time periods can be 
measured by replacing the growth medium. In in vivo as-
sessments, miRNA activity can be detected in as little as  
2.5 μL of peripheral blood. 
We initially tested CMV promoter-driven Gluc sensors 
and found that they could detect activity of miRNAs ex-
pressed at high and low levels in the liver. By co-injection 
of a Fluc internal control, we confirmed that the change in 
Gluc expression was caused by the insertion of miRNA 
target sites. We then found that different doses of sensors 
showed similar efficiency for monitoring miRNA in vivo. 
RT-qPCR showed hydrodynamic injection or expression of 
miRNA target sequence in liver did not change the miRNA 
levels in the liver. Although the CMV-promoter-based sen-
sors could be applied to the long-term monitoring of 
miRNAs in vitro, they were ineffective in vivo because Gluc 
expression decreased within 24 h because of CMV-pro-    
moter silencing. To generate sensors that are more suitable 
for use in mouse liver, we replaced the CMV promoter with 
the CAG promoter and demonstrated that CAG-based sen-
sors can be used to monitor miR-122 and miR-142 activity in 
mouse liver over long periods. Using CAG-based sensors, we 
successfully detected endogenous and exogenous miR-34a 
activity. Thus, our sensors provide a sensitive and quantita-
tive method for long-term ex vivo monitoring of in vivo 
miRNA activity. 
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Our Gluc-miRT sensors have several advantages. First, 
the use of Gluc-miRT sensors to assay blood miRNA activ-
ity avoids the killing of test animals and allows miRNA 
activity to be monitored in a single animal over a long pe-
riod. Second, our method is faster and more convenient than 
imaging assays, which involve substrate injection and anes-
thesia prior to measurement. Imaging assays are useful for 
localizing signals to specific tissues; however, a blood assay 
is more convenient for continuous monitoring of in vivo 
processes. Third, because of its short half-life in the blood 
(approximately 20 min), Gluc does not accumulate over 
time, allowing dynamic miRNA activity to be monitored. 
Finally, Gluc-miRT sensors are extremely sensitive for 
monitoring miRNA activity. When we used a miRNA sen-
sor with CMV-driven Fluc as the reporter to monitor 
miR-122 activity in mouse liver, repression of only 
33.7-fold at 12 h was detectable (data not shown). Similar 
application of the CMV/Gluc-miR-122T sensor detected a 
425.4-fold repression.  
In conclusion, we have established a simple method for 
ex vivo monitoring of in vivo microRNAs in mouse liver. 
The strategy that we employed can be applied to other 
miRNAs, as well as to other organs and cells. The technol-
ogy that we have developed has the potential to facilitate 
studies focused on the in vivo role of miRNAs. 
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